Myelin oligodendrocyte glycoprotein antibody-associated disease combined with other neuroimmune antibodies
10.3760/cma.j.cn113694-20240629-00441
- VernacularTitle:合并其他神经免疫抗体的抗髓鞘少突胶质细胞糖蛋白抗体相关疾病
- Author:
Xiaonan ZHONG
1
;
Xia WANG
;
Wei QIU
;
Xueqiang HU
;
Zhengqi LU
Author Information
1. 中山大学附属第三医院神经内科，广州 510630
- Publication Type:Journal Article
- Keywords:
Myelin oligodendrocyte glycoprotein;
Immunoglobulin G;
Antibody-associated disease;
Biological markers;
Double positive
- From:
Chinese Journal of Neurology
2025;58(2):204-209
- CountryChina
- Language:Chinese
-
Abstract:
Although myelin oligodendrocyte glycoprotein (MOG)-IgG is a biological marker for diagnosing MOG antibody-associated disease (MOGAD), the specificity of MOG-IgG in disease diagnosis remains controversial. In clinical practice, there is significant heterogeneity in MOGAD patients with low titer of MOG-IgG and low titer MOG-IgG can even be detected in asymptomatic populations. At the same time, MOG-IgG-positive individuals often combine with the positivity of other multiple autoimmune antibodies in the nervous system. Therefore, the relationship between MOG-IgG and MOGAD is complex, and the pathogenesis of MOGAD may involve immune factors other than MOG-IgG. This article reviews the research progress of MOGAD combined with other neuroimmune antibodies, assisting in the early identification and treatment of such diseases by clinical physicians in the future.
